



Vaccines and Global Health: The Week in Review
29 October 2022 :: Issue 677
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 27,000 entries.***

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Organization Announcements](#)

::

*Journal_***Watch**

Milestones, Perspectives

.....
.....

TB

Global tuberculosis report 2022

WHO

October 2022 :: 68 pages

PDF: <https://apps.who.int/iris/rest/bitstreams/1474924/retrieve>

Overview

The WHO Global Tuberculosis Report 2022 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

The 2022 edition of the report is as usual, based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2022, 202 countries and territories with more than 99% of the world's population and TB cases reported data.

Please note that direct comparisons between estimates of TB disease burden in the latest report and previous reports are not appropriate. The most recent time-series of estimates are published in this global TB report

.....

Tuberculosis deaths and disease increase during the COVID-19 pandemic

27 October 2022

News release

An estimated 10.6 million people fell ill with tuberculosis (TB) in 2021, an increase of 4.5% from 2020, and 1.6 million people died from TB (including 187 000 among HIV positive people), according to the World Health Organization's [2022 Global TB report](#). The burden of drug-resistant TB (DR-TB) also increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant TB (RR-TB) in 2021. This is the first time in many years an increase has been reported in the number of people falling ill with TB and drug resistant TB. TB services are among many others disrupted by the COVID-19 pandemic in 2021, but its impact on the TB response has been particularly severe. Ongoing conflicts across Eastern Europe, Africa and the Middle East have further exacerbated the situation for vulnerable populations.

"If the pandemic has taught us anything, it's that with solidarity, determination, innovation and the equitable use of tools, we can overcome severe health threats. Let's apply those lessons to tuberculosis. It is time to put a stop to this long-time killer. Working together, we can end TB," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

Continued challenges with providing and accessing essential TB services have meant that many people with TB were not diagnosed and treated. The reported number of people newly diagnosed with TB fell from 7.1 million in 2019 to 5.8 million in 2020. There was a partial recovery to 6.4 million in 2021, but this was still well below pre-pandemic levels...

The report notes a decline in global spending on essential TB services from US\$6 billion in 2019 to US\$5.4 billion in 2021, which is less than half of the global target of US\$13 billion annually by 2022. As in the previous 10 years, most of the funding used in 2021 (79%) was from domestic sources. In other low- and middle-income countries, international donor funding remains crucial. The main source is the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund). The United States Government is the largest contributor of funding to the Global Fund and is also the largest bilateral donor; overall, it contributes close to 50% of international donor funding for TB.

"The report provides important new evidence and makes a strong case on the need to join forces and urgently redouble efforts to get the TB response back-on-track to reach TB targets and save lives," said Dr Tereza Kasaeva, Director of WHO's Global TB Programme. "This will be an essential tool for countries, partners and civil society as they review progress and prepare for the 2nd UN High Level Meeting on TB mandated for 2023."

.....

G20 health ministers appeal for more TB funding and deliver six key actions to strengthen the global health architecture

28 October, Geneva – World health leaders launched a call to action on financing tuberculosis (TB) today in Bali, Indonesia, where they met ahead of the G20 Summit to discuss strengthening global health architecture.

G20 members recognize that lack of adequate financing remains the top obstacle to ending the TB epidemic, and stress that global investments must increase fourfold by 2030 to meet the targets set for ending this preventable and treatable disease.

The call to action coincides with the recent launch of the World Health Organization's 2022 Global TB Report, which laid bare the devastating consequences of the COVID-19 pandemic on global efforts to control TB.

The report showed an increase for the first time in many years in the number of people falling ill with TB and drug-resistant TB, along with a decline in 2021 in global spending on essential TB services. At the same time, G20 members underscored the critical role Unitaid plays in the TB response as the world's largest multilateral donor to TB research and development, striving for equitable access to life-saving diagnostics and treatment...

.....

.....

One Health

Putting Pandemics Behind Us: Investing in One Health to Reduce Risks of Emerging Infectious Diseases

World Bank Group

Berthe, Franck Cesar Jean; Bali, Sulzhan Rameshwari; Batmanian, Garo J..

October 20, 2022

Report PDF:

<http://documents1.worldbank.org/curated/en/099530010212241754/pdf/P17840200ca7ff098091b7014001a08952e.pdf>

Overview

The COVID-19 crisis brought home the high costs of pandemics, triggering a historic setback in the fight against poverty. It also reinforced the interconnections between people, planet and economy, calling attention to the zoonotic nature of pathogens spilling over from animals to people. To decrease their burden, we must focus on prevention. The One Health approach proposes a way forward to reduce risk of spillover. Recognizing that the health and well-being of humans, animals, and their shared ecosystems are interdependent, One Health is designed as an integrated, practical, multisectoral framework for pandemic prevention. By stopping infectious diseases from spilling over to people and spreading to become pandemics, One Health provides a solid foundation for global health security and improved development outcomes at much lower societal and economic costs. This report aims to shed light on the benefits of prevention to serve as a wake-up call for policymakers and finance ministers alike. The report also outlines an investment framework and One Health architecture for zoonotic disease prevention. As you will read on these pages, compared to the sky-high cost of bringing pandemics under control, relatively modest investments in prevention will pay huge dividends.

FIGURE 6.
One Health investment
framework to reduce
pandemic risk



.....
.....

Pandemic Response

[Biotechs, developing countries vaccine manufacturers and pharma unite behind a proposal to G20 and G7](#)

23 October 2022

- The vaccines innovators and manufacturers who have produced over 15 billion COVID-19 vaccines to date are making a proposal that would ensure new vaccines developed for future global pandemics would reach all priority populations equally, wherever they live, thereby addressing a key element of vaccine inequity that hampered the roll out of COVID-19 vaccines in many lower-income countries.
- **The trade bodies representing vaccines innovators and manufacturers who have collaborated closely to bring their collective expertise and knowhow in response to this pandemic, have agreed to jointly endorse the [Berlin Declaration](#) framework which outlines how the industry would reserve an allocation of real-time production of vaccines for distribution to priority populations in lower-income countries for future global pandemics.**
- **The vaccine makers invite the G7, G20 to take up industry's proposal as an integral part of their future pandemic planning** and call on high-income countries to take steps to ensure the necessary political and financial support to deliver the vaccines to lower income countries to prioritise improving their health systems so they are better prepared to distribute the vaccines.

24 October 2022 – The Biotechnology Innovation Organization (BIO), Developing Countries Vaccine Manufacturers' Network (DCVMN) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) have been key players in the historic effort to scale up the manufacturing of COVID-19 vaccines. Today, the three trade bodies representing vaccines innovators and manufacturers who have acquired unique expertise and have worked closely to bring solutions to the COVID-19 pandemic are contributing to the G7 and G20 discussions an offer of a practical solution to vaccine equity for future pandemics. The proposal intends to ensure that new vaccines developed for future pandemics would reach priority vulnerable populations wherever they live at the same time, and as rapidly as possible. At the close of the meeting "Global Equity & Timely Access: COVID-19 and Beyond" today, hosted by DCVMN in Pune, India, the trade bodies announced that they would join forces in support of the "biopharmaceutical industry vision for equitable access in pandemics" which was launched in July 2022 in Berlin.

To date nearly 16 billion doses of vaccines for COVID 19 have been produced. In the first year of the pandemic 11 billion were produced of which 1 billion were specifically directed to COVAX for distribution to lower income countries. The historic scale up was facilitated by over 350 business-to-business partnerships, in the form of voluntary licenses and technology transfers. By supporting the vision for equitable access in pandemics, vaccine innovators and manufacturers acknowledge that while innovation, business to business voluntary collaboration and manufacturing scaling up succeeded in an unprecedented way during COVID-19, efforts to achieve equitable access were not fully realized.

The experience garnered by vaccine innovators and manufacturers in this pandemic has led to an agreement on a proposal to not only aim for faster manufacturing scale up, but more importantly, to ensure that in future pandemics new vaccines would reach priority vulnerable populations wherever they lived at the same time. Specifically, the proposal offers to reserve a real-time allocation of vaccines production for vulnerable populations in lower-income countries.

The three trade bodies invite the G7, G20, as well as multilateral organizations and other decision-makers to accept this practical solution and include it in their future pandemic preparedness response plans, whilst impressing upon governments that for the proposal to succeed the health systems in lower-income countries need to be better prepared to absorb and deliver

vaccines and treatments, while high income countries need to provide the necessary political and financial support.

The vaccine innovators and manufacturers also outline their support for collaborations, a geographically diverse sustainable manufacturing footprint and mechanisms for rapidly scaling-up supply in a future pandemic. They agree to build on existing manufacturing partnerships, business-to-business agreements set up in advance, ongoing capability development and voluntary licensing and/or early, voluntary technology transfer where this will facilitate rather than impede scale up and global supply. These efforts rely on having a strong innovation eco-system, the removal of regulatory and trade barriers to export. **Finally, the proposal emphasizes that without robust pandemic plans to deliver pandemic vaccines, treatments and diagnostics and care to populations in all countries, as well as the ability to export vaccines from where they are made, attempts to improve equity will falter.**

.....
.....

Change Cannot Wait: Building Resilient Health Systems in the Shadow of COVID-19

World Bank

October 25, 2022 Type: Publication

The COVID-19 pandemic has shown the world that fundamental change in health systems cannot wait. The probability of a pandemic with similar impact to COVID-19 is set to increase three-fold in the next few decades due to increasing risk drivers, such as urbanization, climate change, land use changes, fragility and conflict, and zoonotic spillovers. This report builds on previous work, leverages new research, and considers countries' frontline experiences during COVID-19. It presents a new framework for making health systems resilient, shows how countries can build them, and where countries and partners can target investments to improve health outcomes.

COVID-19 revealed structural weaknesses in health systems worldwide and negatively impacted individuals, societies, and economies. Countries need to take transformative action to build stronger, more resilient health systems that can better prevent, prepare for, and respond to future shocks while maintaining essential health services.

Investments in health system resilience improve health and productivity, reduce mortality and morbidity from crises averted, and enable equity and public trust not just during crises but also between crises.

Key Messages:

- Pandemic prevention, preparedness, and response (PPR) is integral to health system resilience (HSR). A country that is not prepared, cannot be resilient.
- Robust health governance is the foundation for resilience and should be a top priority
- Resilience goes beyond the health sector and requires cross-sectoral partnerships that include civil society and partners such as the private sector.
- To boost health system resilience, countries need to:
 - Invest in stronger public health institutions
 - Improve early warning functions
 - Expand community health workforce
 - Prioritize and track investments
 - Strengthen community engagement

- Reshape health service delivery
- With shrinking health budgets following the COVID-19 crisis response, countries need to set priorities for high-yield resilience spending. The most impactful and cost-effective public investments are those that strengthen upstream interventions, especially public health functions, health promotion, disease prevention and primary health care.
- Resilient health systems are integrated systems that are:
 - aware of threats and risk drivers
 - agile in response to evolving needs
 - absorptive to contain shocks
 - adaptive to minimize disruptions

The World Bank has long been committed to helping developing countries build stronger, more resilient health systems and provide quality, affordable health services to everyone – especially to the poorest and most vulnerable populations.



ACT-Accelerator launches six month plan as world transitions to long-term COVID-19 control

28 October 2022

News release

- Plan sets out the partnership's key priorities and ways of working, as countries transition to managing COVID-19 as a long-term public health issue
- The plan's focus is on vaccinating high-risk populations, introducing new treatments, boosting testing and securing sustained access to COVID-19 tools
- The Access to COVID-19 Tools Accelerator is a global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

The Access to COVID-19 Tools (ACT) Accelerator today launches its plan for the next six months, setting out how, as a partnership of global health agencies working alongside government, civil society and other partners, it will support countries as the world transitions to long-term COVID-19 control.

Recognizing the evolving nature of the COVID-19 virus and pandemic, the plan outlines changes to ACT-A's set-up and ways of working, to ensure countries continue to have access to COVID-19 tools in the longer term, while maintaining the coalition's readiness to help address future disease surges.

Developed through a consultative process with ACT-A agencies, donors, industry partners, civil society organizations (CSOs) and Facilitation Council members, **the plan summarizes priority areas of focus for the partnership's pillars, coordination mechanisms and other core functions**, and highlights the work to be maintained, transitioned, sunset, or kept on standby. The transition plan supports the work of ACT-A agencies as they evolve the financing, implementation and mainstreaming of their COVID-19 efforts.

The next phase of ACT-A partners' work will centre on three overarching areas:

[1] Focusing research and development (R&D) and market shaping activities to ensure a pipeline for new and enhanced COVID-19 tools

[2] Securing institutional arrangements for sustained access for all countries to COVID-19 vaccines, tests and treatments, including oxygen

[3] Concentrating in-country work on new product introduction (e.g., new oral antivirals for those at highest risk) and protection of priority populations (e.g., full vaccination of health care workers and older populations), in support of national and international targets

"As the world moves towards managing COVID-19 over the long-term, ACT-A will continue to support countries by providing access to vaccines, tests, and treatments," said WHO Director-General Dr Tedros Adhanom Ghebreyesus. "But as this plan lays out, we still have a lot of work to do to achieve equitable access to these life-saving tools, with health workers and at-risk populations as our top priority."...

The ACT-Accelerator is the world's only end-to-end solution for accelerating the development of, and equitable access to, COVID-19 vaccines, tests and treatments...The Transition Plan can be accessed [here](#).

.....
.....

IFPMA Response to the Release of the ACT-A Evaluation Report

28 October 2022

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) was a founding member of ACT-A when it was launched in April 2020. We welcomed the vision of the ACT-A to involve the private sector, including the innovative pharmaceutical industry, to join this unique global collaboration set up to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines in the wake of the pandemic.

After two intensive years of collective response to the pandemic, we welcomed the opportunity to contribute to the consultation process (including the survey and interview with Thomas Cueni, Director General of IFPMA), which has resulted in the ACT-A Evaluation Report. We appreciate having the opportunity to provide comments on the report.

We were pleased to see the report flag a number of key elements that we considered either instrumental to ACT-A's success, or detrimental to delivering on its mission, such as the lack of available funding for procurement at the onset of the pandemic, insufficient country readiness, the need to invest in health system strengthening, and the importance of open trade. In general, we would like to indicate that we had been expecting the report to be a robust analysis providing evidence-based recommendations. As it currently stands, we feel it has been limited to a summary of the different views shared by participants contributing to the survey and interviews

We would like to share several key concerns:

First, the report failed to evaluate robustly ACT-A's performance per se (separately from the performance of the different pillars). The report should have analyzed ACT-A's governance mechanism and how it contributes or not to its success. The report was a missed opportunity to underscore what the real-life experience of the COVID-19 pandemic response has shown – namely that a multistakeholder partnership that includes industry, public agencies, multilateral organizations, financial institutions, governments, civil society, and philanthropic organizations is the only viable solution to managing pandemic crises. While this was the basis upon which ACT-A was set up,

engagement with the private sector has regrettably been uneven across the different ACT-A pillars over the past two years. While COVAX's approach was inclusive and manufacturers including IFPMA, as well as developing countries vaccine manufacturers DCVMN, had opportunities to share their expertise, the same could not be said for the therapeutics pillar. We resorted to publishing an Open Letter on ACT-A Therapeutics and Ongoing Roadblocks to Enhancing Access^[1] to this effect. We believe the report should have underscored the incorporation of this inclusiveness principle into inter-pandemic governance mechanisms.

Second, we were surprised that the report failed to mention the key role the pharmaceutical industry played in delivering on ACT-A's mission, in particular with respect to the acceleration of development and production of COVID-19 tests, treatments, and vaccines. In just two years, the innovative pharmaceutical industry has developed COVID-19 vaccines and treatments at record speed and in historic quantities, with 47 vaccines authorized or approved by at least one country, 36 approved therapeutics worldwide, 381 manufacturing deals for COVID-19 vaccines with a total of 15 billion vaccines produced, and 148 manufacturing deals for therapeutics. Supply very swiftly was able to outstrip demand^[2].

Third, the report presents technology transfer as an underused solution in the COVID-19 response. It fails to acknowledge the unprecedented effort of the pharmaceutical industry to facilitate access, including through voluntary agreements, many of which featured technology transfer (approx. 88%). In just the first year of COVID-19 vaccines, there were more than 300 manufacturing and production deals around the globe, the vast majority of which (approx. 75%) involve some sort of licensing and transfer of technology, and at least 30 of them on mRNA vaccines.

Furthermore, while the report largely relays calls for even greater levels of COVID-19 technology transfer, particularly for low-income countries, it does not provide a robust analysis of its likelihood for success and impact. While addressing COVID-19 in these countries is critically important, there are many complex factors that must be addressed to ensure the safe, high-quality production of these vaccines, including those related to site selection and capabilities, national regulations and licensure requirements, and workforce skills.

With regards to therapeutics, our member companies have signed voluntary license agreements (bilaterally and through Medicines Patent Pool) along with enabling the transfer of technology to scale up sublicensees' manufacturing capabilities. Our member companies have also engaged with ACT-A's procurement partners to put in place timely supply agreements for several million treatment courses to reach LMICs, while also submitting for emergency and full regulatory approvals and WHO pre-qualification in record time. For all this, our companies continue to adhere to tiered pricing as a guiding principle for access.

Despite these efforts, we remain concerned that COVID-19 vaccines and treatments are still not reaching those who need them in a timely and efficient manner due to a number of issues, several of which rest with ACT-A. We believe that the world should aim to do better in the future – by preparing to respond faster and more equitably. No one stakeholder alone can fully address such issues, and we are committed to collaborating with all relevant actors.

In July 2022, the pharmaceutical industry launched the "Berlin Declaration – biopharmaceutical industry vision for equitable access in pandemics," which presents global leaders with a proposal that could help ensure the supply of pandemic vaccines, treatments, and diagnostics are delivered as early

as possible in future pandemics to those who need them most. The declaration is an acknowledgement that, while innovation and manufacturing scaling-up succeeded in an unprecedented manner during COVID-19, efforts to achieve equitable access were not fully realized. The absence of an adequate financing mechanism upfront and a lack of country readiness played an important role in inhibiting equitable and timely access to vaccines.

In line with the Declaration, IFPMA is calling for discussions with G7, G20, multilateral organizations and other decision-makers involved in pandemic preparedness to explore how industry's offer to prioritize and reserve an allocation of real-time production for distribution to priority populations in lower-income countries would contribute towards the holistic and equitable solution the world needs.

.....
.....
.....

PHEIC

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 28 Oct 2022

Confirmed cases :: 626 337 158

Confirmed deaths :: 6 566 610

Vaccine doses administered: 12 830 378 906

.....

[TAG-VE statement on Omicron sublineages BQ.1 and XBB](#)

27 October 2022

Statement

[Excerpt]

As part of its ongoing work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution ([TAG-VE](#)) met on the 24 October 2022 to discuss the latest evidence on the Omicron variant of concern, and how its evolution is currently unfolding, in light of high levels of population immunity in many settings and country differences in the immune landscape. In particular, the public health implications of the rise of some Omicron variants, specifically XBB and its sublineages (indicated as XBB*), as well as BQ.1 and its sublineages (indicated as BQ.1*), were discussed.

Based on currently available evidence, the TAG-VE does not feel that the overall phenotype of XBB* and BQ.1* diverge sufficiently from each other, or from other Omicron lineages with additional immune escape mutations, in terms of the necessary public health response, to warrant the designation of new variants of concern and assignment of a new label.

The two sublineages remain part of Omicron, which continues to be a variant of concern.

This decision will be reassessed regularly. If there is any significant development that warrant a change in public health strategy, WHO will promptly alert Member States and the public...


.....

Weekly epidemiological update on COVID-19 – 26 October 2022

Overview

Globally, the number of new weekly cases decreased by 15% during the week of 17 to 23 October 2022 as compared to the previous week, with over 2.6 million new cases reported. The number of new weekly deaths decreased by 13% as compared to the previous week, with over 8500 fatalities reported. As of 23 October 2022, over 624 million confirmed cases and over 6.5 million deaths have been reported globally.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 23 October 2022**



.....

.....

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 29 Oct 2022

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]



41

vaccines approved for use by at least one national regulatory authority ¹



11

vaccines in WHO's Emergency Use Listing



1.82bn

doses shipped through COVAX to 146 countries



\$2-\$40

reported vaccine price range per dose



17.9bn

doses secured globally



45K

novel oral antiviral therapeutic treatments arrived in 4 countries




Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 29 Oct 2022]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.



Duke – Launch and Scale Speedometer

[The Race for Global COVID-19 Vaccine Equity](#)

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)



Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.
Donut charts are ordered by proportion of pledged donations shipped.

■ Pledged doses
■ Total Shipped

Country Category:

Top 10 Donating Countries



Remaining	Total Shipped
715,298,358	1,489,085,840

Data updated on October 28th 2022

Duke | GLOBAL HEALTH
Innovation Center

.....

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

15 Oct 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 121M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 12.9B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 380M

Other Delivered (Number of Doses): 400M


Total Delivered (Number of Doses): 780M

Total Administered (Number of Doses): 520M



Global COVID-19 Access Tracker

<https://www.covid19globaltracker.org/>





Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **29 Oct 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



.....
.....

Our World in Data

[Coronavirus \(COVID-19\) Vaccinations](#) [Accessed 29 Oct 2022]

:: [67.9%](#) of the world population has received at least one dose of a COVID-19 vaccine.

:: [12.88 billion doses](#) have been administered globally, and [2.43 million](#) are now administered each day.

:: [23.1%](#) of people in low-income countries have received at least one dose.

.....
.....

U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

HHS

News

No new digest content identified.

FDA

Press Announcements

No new digest content identified.

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

No new digest content identified.

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates [Selected]

News

[Ebola outbreak in Uganda, as of 26 October 2022](#)

Epidemiological update - 28 Oct 2022

News

[Weekly COVID-19 country overview](#)

Epidemiological update - 28 Oct 2022

News

[Joint ECDC-WHO/Europe monkeypox surveillance bulletin](#)

Epidemiological update - 26 Oct 2022

News

[Monkeypox situation update, as of 25 October 2022](#)

Epidemiological update - 26 Oct 2022

.....
.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

<https://africacdc.org/covid-19-vaccination/>



Africa CDC COVID-19 Vaccine Dashboard

Safeguarding Africa's Health

Vaccine Overview

Vaccination Coverage

Vaccine Supply

Vaccine Utilization

Vaccine Policy

Vaccine Delivery Targets

Member State Vaccine Summary

1006M

Vaccine Doses Received

68.9%

% Doses Utilized

693.6M

Vaccine Doses Administered

23.2%

% Coverage (Fully Vaccinated)

.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

No new digest content identified. Last press release issued 31.08.2022.

.....
.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
29 October 2022, 08:00
IST (GMT+5:30)

(↑↓ Status change since
yesterday)

Active (0.04%)

18802

Discharged (98.77%)

44102852

Deaths (1.18%)

529008

COVID-19 Vaccination
as on : 29 October
2022, 08:00 IST
(GMT+5:30)

Total Vaccination : 2,19,62,18,338 (1,72,838 ↑)

Government of India – Press Information Bureau

Latest Press Releases

No new digest content identified.

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China's COVID response in general, or in Shanghai, Beijing or other China locations.]

.....
.....
.....

PHEIC

Monkeypox

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/situations/monkeypox-oubreak-2022>

No new situation report identified since 19 Oct 2022 edition.

.....
.....
.....

PHEIC

Polio

Polio this week as of 26 Oct 2022 - GPEI

:: 24 October marked World Polio Day and partners and countries around the world used the opportunity to raise awareness and resources for polio eradication. The WHO European Regional Office held an event celebrating 20 years since WPV certification. In Geneva, Rotary and WHO joined forces to discuss how the organization's efforts to eradicate polio can now be applied to broader maternal and child health issues. Many thanks to all partners, friends and countries who participated to make World Polio Day a success around the world.

:: In a newly released video, GPEI Director Aidan O'Leary's shares a message on the important outcomes of last week's polio pledging moment in Berlin.

:: "When you put polio drops in a child's mouth, you feel happiness inside, happiness that you have saved a child," she says. "I urge people to come and work for this feeling. This work brings a lot of peace."- Shiza, a polio vaccinator in Pakistan. Read more...

:: nOPV2 rollout: Approximately 500 million doses of nOPV2 have been administered across 23 countries under its WHO Emergency Use Listing (EUL) to date. An additional 16 countries have met the requirements for nOPV2 use in the event of an outbreak. More information on nOPV2.

:: In the Democratic Republic of the Congo, three women are helping improve the lives of polio survivors and other people living with disability. Check out their story in this UN Foundation blog post.

:: "It's not the first time such targets have been offered. But what's different this time around is that, in addition to mass vaccination campaigns, the initiative's new strategy will be intensely focused on finding targeted ways to reach missed communities and take advantage of opportunities to become more integrated with other essential services."- Seth Berkley, CEO of Gavi. Read more...

Summary of new polioviruses this week:

- Afghanistan: one WPV1 positive environmental sample
- Algeria: two cVDPV2 positive environmental samples
- DR Congo: one cVDPV1 case and six cVDPV2 cases
- Niger: one cVDPV2 case
- Nigeria: one cVDPV2 case

.....
.....

UN OCHA – Current Emergencies

Current Corporate Emergencies

Afghanistan

:: Afghanistan: Snapshot of Population Movements, January to October 2022 (As of 24 October 2022)

Northern Ethiopia

No new digest content identified.

Somalia

No new digest content identified.

Ukraine

Ukraine: Situation Report, 26 Oct 2022

.....
.....

WHO & Regional Offices [to 29 Oct 2022]

<https://www.who.int/news>

Selected News/Announcements/Statements

28 October 2022

News release

ACT-Accelerator launches six month plan as world transitions to long-term COVID-19 control

27 October 2022

Statement

TAG-VE statement on Omicron sublineages BQ.1 and XBB

27 October 2022

News release

Tuberculosis deaths and disease increase during the COVID-19 pandemic

24 October 2022

Departmental news

Universal access to safe drinking water requires increased investment backed by strong government institutions - WHO, UNICEF, World Bank

.....

WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

Selected Speeches

28 October 2022

Speech

WHO Director-General's opening remarks at 12th ACT Accelerator Facilitation Council Meeting – 28 October 2022

27 October 2022

Remarks

WHO Director-General's opening remarks at Member State Information Session on COVID-19 and other issues – 27 October 2022

25 October 2022

Remarks

WHO Director-General's remarks at the World Bio Summit 2022

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: [Contact tracers and village health teams take on Ebola in Uganda](#) 27 October 2022

WHO Region of the Americas PAHO

:: 27 Oct 2022

Tuberculosis deaths and disease increase during the COVID-19 pandemic

Geneva, 27 October 2022: An estimated 10.6 million people fell ill with tuberculosis (TB) in 2021, an increase of 4.5% from 2020, and 1.6 million people died from TB (including 187 000 among HIV positive people), according to the World Health Organization's 2022 Global TB report. The burden of drug-resistant TB (DR-TB) also increased by 3%...

:: 24 Oct 2022

Q&A with PAHO Chief of Immunization for World Polio Day

Washington, DC, 24 October 2022 (PAHO)- In 1994, the Region of the Americas was the first in the world to be certified polio-free by the World Health Organization (WHO), a milestone achieved after concerted effort by countries with the support of the Pan American Health Organization (PAHO). But vaccination rates in children with all three...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 24 October 2022 Statement

European Region 20 years polio-free: a celebratory moment but a fragile legacy

WHO Western Pacific Region

:: [Asia-Pacific health ministers work to reach the unreached, combat cervical cancer and promote mental health](#) 28 October 2022

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

28 October 2022 | [Ebola Disease caused by Sudan virus - Uganda](#)

On 20 September 2022, the health authorities in the Republic of Uganda declared an outbreak of Ebola disease caused by Sudan ebolavirus (SUDV), after a case was confirmed in a village in Madudu sub-county in Mubende district, central Uganda on 19 September.

As of 26 October, a total of 115 confirmed and 21 probable cases, including 32 confirmed and 21 probable deaths (CFR among confirmed cases: 27.8%) have been reported. Overall, 15 cases with four deaths have been reported among healthcare workers...

.....

WHO Events

<https://www.who.int/news-room/events/1>

[Selected]

No new digest content identified.

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected Titles

27 October 2022

[Global tuberculosis report 2022](#)

25 October 2022

[WHO fungal priority pathogens list to guide research, development and public health action](#)

24 October 2022

[State of the world's drinking water: An urgent call to action to accelerate progress on ensuring safe...](#)

.....

.....

.....

CDC/ACIP [U.S.] [to 29 Oct 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases

No new digest content identified.

.....

[ACIP Meetings](#)

Next ACIP Meeting

No 2022 meetings identified.

.....

MMWR Weekly: Current Volume (71)

October 28, 2022 / No. 43

[PDF of this issue](#)

- [Influenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season — Chile, 2022](#)
- [Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 — United States, January–July 2022](#)
- [Vital Signs: Influenza Hospitalizations and Vaccination Coverage by Race and Ethnicity—United States, 2009–10 Through 2021–22 Influenza Seasons](#)

- [Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox — United States, May 22–October 10, 2022](#)
- [Characteristics of JYNNEOS Vaccine Recipients Before and During a Large Multiday LGBTQIA+ Festival — Louisiana, August 9–September 5, 2022](#)
- [A Health Equity Approach for Implementation of JYNNEOS Vaccination at Large, Community-Based LGBTQIA+ Events — Georgia, August 27–September 5, 2022](#)
- [Notes From the Field: Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code–Level Social Vulnerability — United States, December 23, 2021–August 28, 2022](#)

.....

[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)

Announcements/reports/data summaries.

.....

.....

Africa CDC [to 29 Oct 2022]

<http://www.africacdc.org/>

News

No new digest content identified.

.....

.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 29 Oct 2022]

<http://en.nhc.gov.cn/>

News

[Oct 29: Daily briefing on novel coronavirus cases in China](#)

On Oct 28, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 377 new cases of confirmed infections.

National Medical Products Administration – PRC [to 29 Oct 2022]

<http://english.nmpa.gov.cn/>

[Chinese mainland reports 214 new local confirmed COVID-19 cases](#)

2022-10-28

The Chinese mainland on Thursday reported 214 locally transmitted confirmed COVID-19 cases, the National Health Commission said Friday.

CCDC [Weekly Reports: Current Volume \(4\)](#)

2022-10-28 / No. 43

[View PDF of this issue](#)

Preplanned Studies: HIV-Positive Men Are More Likely to Be Hyper Linked Within College Student Social Network — Northeast China, 2017–2018

Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, July 2022

.....
.....
.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 29 Oct 2022]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 29 Oct 2022]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

[Bill & Melinda Gates Foundation Announces New Initiatives to Support Locally Led R&D for Global Health and Gender: Calls for Proposals](#)

OCTOBER 24, 2022

... As part of the Grand Challenges Global Call to Action, a 10-year initiative announced at last year's meeting to help ensure scientists and institutions in low- and middle-income countries (LMICs) play a central role in shaping the global R&D agenda, the foundation announced two new Grand Challenges initiatives:

:: Pathogen Genomic Surveillance and Immunology in Asia: This is an invitation for proposals from :: investigators in South and Southeast Asia to design and pilot a genomic surveillance program or develop capacity for immunology and immune sequencing of SARS-CoV-2 to inform epidemic response. Up to \$300,000 per year for up to two years will be available for each project, with potential additional funding for projects that include a focus on monoclonal antibody discovery.

:: Building Data Modeling Capacity for Gender Equality: This is an invitation for proposals from investigators in low- and middle-income countries for projects aimed at addressing disparities and gaps affecting women and girls in health. This initiative is focused on innovative approaches to modeling that advance gender equality. Each project will receive up to \$500,000 over one to three years...

Bill & Melinda Gates Medical Research Institute [to 29 Oct 2022]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of

mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 29 Oct 2022]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 29 Oct 2022]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions of [Vaccines and Global Health: The Week in Review](#) are [available here](#).

:: [Informed Consent: A Monthly Review – October 2022](#) is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 29 Oct 2022]

<http://cepi.net/>

Latest News

News; Publications

[CEPI and SK bioscience partner to advance mRNA vaccine technology to build vaccine library, enable rapid response against Disease X](#)

Up to \$40 million in funding committed to support development of mRNA-vaccine candidates against Lassa Fever virus and Japanese Encephalitis virus

25 Oct 2022

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 29 Oct 2022]

<https://cioms.ch/>

News; Publications

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 29 Oct 2022]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 29 Oct 2022]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 29 Oct 2022]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

27 October 2022

[Fifteen 'EPI-Biostat Fellows' start their training at the University of Cape Verde](#)

27 October 2022

[Recruitment of EPI-Biostat Fellows' at London School of Hygiene & Tropical Medicine completed](#)

Emory Vaccine Center [to 29 Oct 2022]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 29 Oct 2022]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified

Evidence Aid [to 29 Oct 2022]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

No new digest content identified.

Fondation Merieux [to 29 Oct 2022]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified

Gavi [to 29 Oct 2022]

<https://www.gavi.org/>

News Releases

28 October 2022

[Lower-income countries push to reach more than 85 million children with measles vaccine](#)

- Following an alarming global rise in measles cases and outbreaks, lower Income countries are accelerating efforts with support from Gavi, the Vaccine Alliance
- Gavi-supported measles campaigns aim to reach more than 85 million children across 22 countries, between 2022 and the first half of 2023

- Gavi has also supported 9 countries respond to outbreaks in 2022, dedicating an additional US\$ 10 million to support outbreak response in lower-income countries

GHIT Fund [to 29 Oct 2022]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified

Global Fund [to 29 Oct 2022]

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 29 Oct 2022]

<https://www.glopid-r.org/news/>

News

Press Room

No new digest content identified.

Hilleman Laboratories [to 29 Oct 2022]

<http://www.hilleman-labs.org/>

News & Insights

[SK bioscience and Hilleman Laboratories to Co-develop New Vaccine Platforms](#)

27 October 2022

Under the agreement, SK bioscience and Hilleman Laboratories will collaborate on end-to-end vaccine research and early-stage development including vaccine platform development, leveraging the development and manufacturing capabilities of both parties, including Hilleman's vaccine and biologics development and manufacturing hub in Singapore, and SK's upcoming Research and Process Development (R&PD) Center in Songdo as well as L-HOUSE, its vaccine manufacturing facility in Andong, South Korea. Both companies are also committed to capacity and capability building in global vaccine expertise across the entire value chain, which is central for pandemic preparedness and response...

HHMI - Howard Hughes Medical Institute [to 29 Oct 2022]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Vaccines Project [to 29 Oct 2022]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 29 Oct 2022]

<https://www.iavi.org/>

Latest News

October 25, 2022

[IAVI to accelerate promising investigational Sudan ebolavirus vaccine development for potential outbreak research and response](#)

Merck will provide the investigational vaccine based on a proven platform technology

ICRC [to 015 Oct 2022]

<https://www.icrc.org/en/whats-new>

What's New [Selected] •

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

[IFFIm returns to market with US\\$ 500 million 3-year bond](#)

25 Oct 2022

The International Finance Facility for Immunisation Company (IFFIm) today priced a US\$ 500 million, 3-year fixed rate bond to provide Gavi, the Vaccine Alliance, with immediately available funding to support routine immunisation in lower-income countries, reaching nearly half the world's children.

[How the World Bank built trust in vaccine bonds](#)

21 Oct 2022

Interview with Doris Herrera-Pol and Heike Reichelt.

[Gavi Annual Progress Report: 2021 was “defining” for IFFIm](#)

21 Oct 2022

From its founding in 2000 to the end of 2021, Gavi has helped to immunise a whole generation – over 981 million children – and prevented more than 16.2 million future deaths, helping to halve child mortality in 73 lower-income countries by the end of 2021. These are a few of the results published in Gavi's 2021 Annual Progress Report.

IFRC [to 29 Oct 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

Millions of people in Asia living in stagnant water at risk of facing deadly diseases

27/10/2022 | Press release

Kuala Lumpur, 27 October 2022 – After unprecedented floods continue to hit many parts of Asia, dangerous un-subsiding flood waters are now the crisis, the International Federation of Red Cross and Red Crescent Societies (IFRC) warns. Men, women, and children are being forced to live out their day-to-day lives in dirty, stagnated water, and are at risk of deadly diseases such as malaria, dengue, cholera, and diarrhoea, not to mention long-term harmful effects to their bodies...

Institut Pasteur [to 29 Oct 2022]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 22 Oct 2022]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Current

News

Dr Salvatore Aricò to be appointed as Chief Executive Officer of the International Science Council

27.10.2022

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 29 Oct 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 29 Oct 2022]

<http://www.ivi.int/>

IVI News & Announcements

IVI welcomes Thailand as a state party

H.E. Anutin Charnvirakul, Thailand's Deputy Prime Minister and Minister of Public Health, made an official visit to IVI: "I strongly believe that a robust collaboration between Thailand and IVI will bring us many opportunities for vaccine research and development, and enable stronger immunization support globally." [...]

10/25/2022

Johns Hopkins Center for Health Security [to 29 Oct 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 29 Oct 2022]

<http://www.msf.org/>

Latest [Selected Announcements]

Uganda

[Overcoming obstacles in the fight against Ebola in Uganda](#)

Project Update 25 Oct 2022

Greece

[People found handcuffed and injured on the Greek island of Lesbos](#)

Press Release 25 Oct 2022

Kenya

[High risk of outbreaks amid poor living conditions for newly arrived refugees in...](#)

Press Release 25 Oct 2022

National Academy of Medicine - USA [to 29 Oct 2022]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academy of Sciences - USA [to 29 Oct 2022]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 29 Oct 2022]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 29 Oct 2022]

<http://www.nih.gov/>

News Releases

No new digest content identified.

PATH [to 29 Oct 2022]

[https://www.path.org/media-center/
Press Releases
Selected Reports/Press Releases](https://www.path.org/media-center/Press%20Releases/Selected%20Reports/Press%20Releases)
No new digest content identified.

Rockefeller Foundation [to 29 Oct 2022]
[https://www.rockefellerfoundation.org/
Selected Reports/Press Releases](https://www.rockefellerfoundation.org/Selected%20Reports/Press%20Releases)
No new digest content identified.

Sabin Vaccine Institute [to 29 Oct 2022]
[https://www.sabin.org/press/
Latest News & Press Releases](https://www.sabin.org/press/Latest%20News%20&%20Press%20Releases)
No new digest content identified.

UNAIDS [to 29 Oct 2022]
[http://www.unaids.org/en
Selected Press Releases/Reports/Statements](http://www.unaids.org/en/Selected%20Press%20Releases/Reports/Statements)
25 October 2022

[**Asia-Pacific youth demand robust action to lower the HIV risk of young key populations**](#)

UNICEF [to 22 Oct 2022]
[https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements \[Selected\]](https://www.unicef.org/media/press-releases/Press%20Releases,%20News%20Notes,%20Statements%20[Selected])
Press release
24 October 2022

[**Cholera outbreak in Haiti hits over 1,700 suspected cases –half of them children**](#)

<https://www.unicef.org/press-releases/cholera-outbreak-haiti-hits-over-1700-suspected-cases-half-them-children>

PORT-AU-PRINCE/PANAMA, 24 October 2022- Since the onset of the cholera outbreak in Haiti, children below 14 years make up nearly half of the 1,700 suspected cases. Gang violence, fuel shortages and street blockades are hindering humanitarian access to safe water and health services for patients, increasing the risks of women and children dying of...

Statement
24 October 2022

[**Cholera outbreaks threaten children's survival in the Middle East**](#)

<https://www.unicef.org/press-releases/cholera-outbreaks-threaten-childrens-survival-middle-east>
AMMAN, 24 October 2022 – "The fast pace of the cholera outbreak in Syria and Lebanon is alarming and the risks of the disease further spreading to other countries in the region call for immediate action. Urgent support is needed to respond and contain the spread of the disease. "The acute epidemic in Syria has left over 20,000 suspected cases with...

News note

24 October 2022

Universal access to safe drinking water requires increased investment backed by strong government institutions – WHO, UNICEF, World Bank

<https://www.unicef.org/press-releases/universal-access-safe-drinking-water-requires-increased-investment-backed-strong>

GENEVA/NEW YORK/WASHINGTON, 24 OCTOBER 2022 - Governments must invest strategically in building safe drinking water systems by not only increasing funding, but also strengthening capacities to plan, coordinate, and regulate service provision, if the world is to achieve universal access t

Unitaid [to 29 Oct 2022]

<https://unitaid.org/>

Featured News

28 October 2022

G20 health ministers appeal for more TB funding and deliver six key actions to strengthen the global health architecture

27 October 2022

The Republic of Korea reaffirms its strong support to Unitaid to ensure equitable access to health tools

Vaccine Equity Cooperative [nee Initiative] [to 29 Oct 2022]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 29 Oct 2022]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 29 Oct 2022]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 29 Oct 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 29 Oct 2022]

<https://wellcome.ac.uk/news>

News. Opinion, Reports
No new digest content identified.

The Wistar Institute [to22 Oct 2022]
<https://www.wistar.org/news/press-releases>

Media

Press Release

Oct. 24, 2022

The Wistar Institute One of Nation's Top 3 Research Institutions for Innovation

Building stronger economies through innovation.

WFPHA: World Federation of Public Health Associations [to 29 Oct 2022]

<https://www.wfpha.org/>

Latest News - Blog

No new digest content identified.

World Bank [to 015 Oct 2022]

<http://www.worldbank.org/en/news/all>

All News

Reaching the unreached: Smart targeting of HIV interventions in India to benefit the most vulnerable populations

Challenge Despite significant reductions in HIV-AIDS since the start of the National AIDS Control Programme (NACP) in 1992, India still had one of the biggest HIV epidemics in the world. The HIV epidemic...

Date: October 27, 2022 Type: Brief

Caribbean health professionals discuss ways to strengthen health system resilience, following COVID-19 impact

CASTRIES, Saint Lucia, October 25, 2022 - In the wake of disruptions to healthcare delivery caused by the COVID-19 pandemic, healthcare policymakers and professionals in several Caribbean...

Date: October 26, 2022 Type: Press Release

Change Cannot Wait: Building Resilient Health Systems in the Shadow of COVID-19

COVID-19 revealed structural weaknesses in health systems worldwide and negatively impacted individuals, societies, and economies. Countries need to take transformative action to build stronger, more resilient...

Date: October 25, 2022 Type: Publication

Prevent Rather than Fight the Next Pandemic with a One Health Approach: World Bank

WASHINGTON, Oct. 24, 2022 – As the world continues to deal with the devastating effects of COVID-19, the World Bank is today releasing a new report that proposes actionable solutions to end the cycle of...

Date: October 24, 2022 Type: Press Release Language: English

World Customs Organization – WCO [to 29 Oct 2022]

<http://www.wcoomd.org/>

Latest News

No new digest content identified.

World Medical Association [WMA] [to 29 Oct 2022]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health (OIE) [to 29 Oct 2022]

<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 29 Oct 2022]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events [Selected]

No new digest content identified.

.....

ARM [Alliance for Regenerative Medicine] [to 29 Oct 2022]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 29 Oct 2022]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 29 Oct 2022]

<http://www.dcvmn.org/>

News; Upcoming events

October 28, 2022

[Shri Soshil Kumar Jain – Obituary](#)

October 25, 2022

[Biotechs, developing countries vaccine manufacturers and pharma unite behind a proposal to G20 and G7 offering a practical solution for better access to vaccines for future pandemics](#)

ICBA – International Council of Biotechnology Associations [to 29 Oct 2022]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 29 Oct 2022]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

[Biotechs, developing countries vaccine manufacturers and pharma unite behind a proposal to G20 and G7](#)

23 October 2022

[IFPMA Response to the Release of the ACT-A Evaluation Report](#)

28 October 2022

[IFPMA statement at the 73rd session of the WHO Regional Committee for Western Pacific: Items](#)

27 October 2022

[IFPMA statement at the 73rd session of the WHO Regional Committee for Western Pacific: Noncommunicable](#)

27 October 2022

International Alliance of Patients' Organizations – IAPO [to 29 Oct 2022]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

Press Releases

No new digest content identified.

PhRMA [to 29 Oct 2022]

<http://www.phrma.org/>

Press Releases

No new digest content identified.

.....

.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - No new digest announcements identified

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

[**Vacunas cubanas muestran altos títulos de neutralización contra ómicron.**](#) [Cuban vaccines show high neutralization titers against omicron.]

Resumen: Las vacunas cubanas han permitido que la COVID-19 en Cuba se comporte de modo diferente al resto del mundo. Las últimas evidencias demuestran altos títulos de neutralización contra la variante ómicron.

Biological E

News - No new digest announcements identified

BioNTech

Press Releases - No new digest announcements identified

Boehringer

Press Releases - No new digest announcements identified

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified

Cinnagen

Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center

Latest News and Events - See Russia above.

GSK

Press releases for media

28 October 2022

[**European Medicines Agency validates ViiV Healthcare's marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention**](#)

The marketing application is based on results from the HPTN 083 and 084 phase IIb/III studies.

28 October 2022

[GSK marketing authorisation application for respiratory syncytial virus older adult vaccine candidate accepted by European Medicines Agency under accelerated assessment](#)

The vaccine was well tolerated with a favourable safety profile.

25 October 2022

[ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody \(bNAb\) offering a potential new approach for the treatment of HIV](#)

Data from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIb

IMBCAMS, China

Home - Website not responding at inquiry

Janssen/JNJ

Press Releases - No new digest announcements identified

Medicago

Media - No new digest announcements identified

Merck

News releases

October 26, 2022

[Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck](#)

October 24, 2022

[European Commission Expands Merck's VAXNEUVANCE™ \(Pneumococcal 15-valent Conjugate Vaccine\) Indication to Include Infants, Children and Adolescents](#)

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified

Novavax

Press Releases - No new digest announcements identified

Pfizer

Recent Press Releases - No new digest announcements identified

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]

<http://shafapharmed.com/>

No news page identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

Press Releases

[SK bioscience and Hilleman Laboratories to Co-develop New Vaccine Platforms](#)

2022.10.27

[SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines](#)

-CEPI supports up to 40 mil. USD for early development of mRNA vaccine platform to SK bioscience;
2022.10.25

Takeda

Newsroom - No new digest announcements identified

Valneva

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

*	*	*	*
*	*	*	*

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 13, 2022 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

Article

[Navigating Pandemic Moral Distress at Home and at Work: Frontline Workers' Experiences](#)

S. A. Miner, B. E. Berkman, V. Altiery de Jesus, L. Jamal & C. Grady

Pages: 215-225

Published online: 26 Apr 2022

Article

[Diversity in IRB Membership: Views of IRB Chairpersons at U.S. Universities and Academic Medical Centers](#)

Sydney Churchill, Emily A. Largent, Elizabeth Taggart & Holly Fernandez Lynch

Pages: 237-250

Published online: 22 Aug 2022

AMA Journal of Ethics

Volume 24, Number 10: E913-1027 Oct 2022

<https://journalofethics.ama-assn.org/issue/health-care-waste>

Health Care Waste

Most health care generated waste is not hazardous, but it is voluminous. Health care organizations have obligations to manage waste in ways that minimize environmental impact and express their status as good citizens of their global, domestic, and regional communities. Resource-rich countries generate on average more than double the amount of hazardous waste per bed per day than resource-poor countries, and waste processing is concentrated in minoritized communities nearly everywhere. Segregating waste and reducing overall volume are key to curbing primary and secondary emissions that contaminate air and water. Decarbonization and moving the health care sector to net-zero emissions are key expressions of sincerity about motivating health equity.

American Journal of Infection Control

October 2022 Volume 50 Issue 10 p1077-1192

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

October 2022 Volume 63 Issue 4 p469-668

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

October 2022 112(10)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 107 (2022): Issue 4_Suppl (Oct 2022)

https://www.ajtmh.org/view/journals/tpmd/107/4_Suppl/tpmd.107.issue-4_Suppl.xml

International Centers of Excellence for Malaria Research (ICEMR): Achievements in the Last Decade

[Reviewed earlier]

Annals of Internal Medicine

October 2022 Volume 175, Issue 10

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 311 October 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/310/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 29 Oct 2022)

[No new digest content identified]

BMJ Global Health

September 2022 - Volume 7 - Suppl 7

https://gh.bmj.com/content/7/Suppl_7

Original research

[Learning health systems in low-income and middle-income countries: exploring evidence and expert insights](#) (21 September, 2022)

Sophie Witter, Kabir Sheikh, Meike Schleiff

Practice

Adapting public health response through lessons learnt: Nigeria's experience from Lassa fever and COVID-19 (21 September, 2022)

Fatima Saleh, Biliamin O Popoola, Chinedu Arinze, Andebutop A. Elisha, Chioma Dan-Nwafor, Lois Olajide, Elsie Ilori, Chinwe Lucia Ochu, Chikwe A Ihekweazu

Co-learning during the co-creation of a dengue early warning system for the health sector in Barbados (21 September, 2022)

Anna M Stewart-Ibarra, Leslie Rollock, Sabu Best, Tia Brown, Avriel R Diaz, Willy Dunbar, Catherine A Lippi, Roché Mahon, Sadie J Ryan, Adrian Trotman, Cedric J Van Meerbeeck, Rachel Lowe

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 29 Oct 2022)

Psychometric evidence of a perception scale about covid-19 vaccination process in Peruvian dentists: a preliminary validation

In the current pandemic context, dental professionals have greater occupational risks due to their healthcare activity, placing their expectations on the vaccine as a means of protection and at the same time h...

Authors: César F. Cayo-Rojas, Nancy Córdova-Limaylla, Gissela Briceño-Vergel, Marysela Ladera-Castañeda, Hernán Cachay-Criado, Carlos López-Gurreonero, Alberto Cornejo-Pinto and Luis Cervantes-Ganoza

Citation: BMC Health Services Research 2022 22:1296

Content type: Research Published on: 28 October 2022

Strengthening vaccination delivery system resilience in the context of protracted humanitarian crisis: a realist-informed systematic review

Childhood vaccination is among the most effective public health interventions available for the prevention of communicable disease, but coverage in many humanitarian settings is sub-optimal. This systematic re...

Authors: Sharif A. Ismail, Sze Tung Lam, Sadie Bell, Fouad M. Fouad, Karl Blanchet and Josephine Borghi

Citation: BMC Health Services Research 2022 22:1277

Content type: Research article Published on: 23 October 2022

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 29 Oct 2022)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 29 Oct 2022)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 29 Oct 2022)

Research article

[Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis](#)

Dose fractionation of a coronavirus disease 2019 (COVID-19) vaccine could effectively accelerate global vaccine coverage, while supporting evidence of efficacy, immunogenicity, and safety are unavailable, espe...

Authors: Bingyi Yang, Xiaotong Huang, Huizhi Gao, Nancy H. Leung, Tim K. Tsang and Benjamin J. Cowling

Citation: BMC Medicine 2022 20:409

Content type: Research article Published on: 25 October 2022

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 29 Oct 2022)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 29 Oct 2022)

[Psychometric properties of public trust in Covid-19 control and prevention policies questionnaire](#)

Public trust is a crucial concept in the COVID-19 pandemic, which determines public adherence with preventive rules as a success factor for disease management. This study aimed to develop and validate a tool t...

Authors: Riaz Alaei Kalajahi, Mohammad Saadati, Saber Azami Aghdash, Ramin Rezapour, Mehdi Nouri, Naser Derakhshani and Koustuv Dalal

Citation: BMC Public Health 2022 22:1959

Content type: Research Published on: 24 October 2022

[A retrospective review of vaccine wastage and associated risk factors in the Littoral region of Cameroon during 2016–2017](#)

Immunization is an effective preventive health intervention. In Cameroon, the Expanded Program on Immunization (EPI) aims to vaccinate children under 5 years of age for free, but vaccination coverage has consi...

Authors: Rene Nkenyi, Gi Deok Pak, Calvin Tonga, Yun Chon, Se Eun Park and Sunjoo Kang

Citation: BMC Public Health 2022 22:1956

Content type: Research Published on: 23 October 2022

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 29 Oct 2022)

[No new digest content identified]

BMJ Evidence-Based Medicine

October 2022 - Volume 27 - 5

<https://ebm.bmj.com/content/27/5>

[Reviewed earlier]

BMJ Open

September 2022 - Volume 12 - 9

<https://bmjopen.bmj.com/content/12/9>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 100(10); 2022 Oct 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/417951/>

[Reviewed earlier]

Cell

Oct 27, 2022 Volume 185 Issue 22 p4039-4248

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 48, Issue 6 Pages: 881-1137 November 2022

<https://onlinelibrary.wiley.com/toc/13652214/current>

Special Issue: The Pervasive Effects of COVID-19 on Children: A Global Perspective

Issue Edited by: Jan Willian Gorter, Evelyn Culnane, Lyndal Hickey, Mark Ferro, Tony Okely

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 112, Issue 4 Pages: 731-916 October 2022

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

September 2022 Volume 44 Issue 9 p1173-1268

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 19 Issue 5, October 2022

<https://journals.sagepub.com/toc/ctja/19/5>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 29 Oct 2022]
[No new digest content identified]

Contemporary Clinical Trials

Volume 121 October 2022
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/121/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 5, Issue 5 / October 2022
<https://www.liebertpub.com/toc/crispr/5/5>
[Reviewed earlier]

Current Genetic Medicine Reports

Volume 10, issue 1, March 2022
<https://link.springer.com/journal/40142/volumes-and-issues/10-1>
[Reviewed earlier]

Current Opinion in Infectious Diseases

October 2022 - Volume 35 - Issue 5
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>
[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020
<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>
[Reviewed earlier]

Developing World Bioethics

Volume 22, Issue 3 Pages: 123-180 September 2022
<https://onlinelibrary.wiley.com/toc/14718847/current>
[Reviewed earlier]

Development in Practice

Volume 32, Issue 8, 2022

<http://www.tandfonline.com/toc/cdip20/current>

Article

[Topics of significance for international development from religions and COVID-19 research](#)

[Susanna Trotta](#), [Olivia Wilkinson](#) & [Katherine Marshall](#)

Pages: 1124-1134

Published online: 19 Jun 2022

Disaster Medicine and Public Health Preparedness

Volume 16 - Issue 5 - October 2022

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

Commentary

[COVID-19 at War: The Joint Forces Operation in Ukraine](#)

[John M. Quinn V](#), [Trisha Jigar Dhabalia](#), [Lada L. Roslycky](#), [James M. Wilson V](#), [Jan-Cedric Hansen](#), [Olesya Hulchiy](#), [Olga Golubovskaya](#), [Mykola Buriachyk](#), [Kondratiuk Vadim](#), [Rostyslav Zauralsky](#), [Oleg Vyrva](#), [Dmytro Stepanyi](#), [Pohil Sergiy Ivanovitch](#), [Alla Mironenko](#), [Volodymyr Shportko](#), [John E. McElligott](#)

Published online by Cambridge University Press: 25 March 2021, pp. 1753-1760

Print publication: October 2022

Policy Analysis

[Discrimination and Bias in State Triage Protocols Toward Populations With Intellectual Disabilities During the COVID-19 Pandemic](#)

[Ashley Brooke Felt](#), [Dionne Mitcham](#), [Morgan Hathcock](#), [Raymond Swienton](#), [Curtis Harris](#)

Published online by Cambridge University Press: 25 March 2021, pp. 1772-1774

Print publication: October 2022

Original Research

[Global Research Activity on Health System Preparedness Against Viral Infectious Disease Outbreaks](#)

[Waleed M. Sweileh](#)

Published online by Cambridge University Press: 18 August 2021, pp. 1959-1965

Print publication: October 2022

Disasters

Volume 46, Issue 4 Pages: 853-1126 October 2022

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 23 Issue 10 6 October 2022

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 28, Number 10—October 2022

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 40 September 2022

<https://www.sciencedirect.com/journal/epidemics/vol/40/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 150 - 2022

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 44, Issue 5 Pages: 1-21 September–October 2022

<https://onlinelibrary.wiley.com/toc/25782363/current>

Protecting healthy volunteers • IRBs and research biopsies

[Reviewed earlier]

Ethics & International Affairs

Spring 2022 (36.1) | March 10, 2022

<https://www.ethicsandinternationalaffairs.org/2022/spring-2022-36-1/>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 24 October 2022

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/24/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 32, Issue 5, October 2022

<https://academic.oup.com/eurpub/issue/32/5>

[Reviewed earlier]

Expert Review of Vaccines

Vol 21 (9) 2022

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

Volume 101, Number 5 September/October 2022

<https://www.foreignaffairs.com/issues/2022/101/5>

[New issue; No relevant content identified]

Forum for Development Studies

Volume 49, 2022 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 24, Issue 10 Pages A1-A6, 1993-2210 (October 2022)

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/24/issue/10>

[New issue; No relevant content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 29 Oct 2022]

[No new digest content identified]

Global Health Action

Volume 15, Issue 1 (2022)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

August 2022 | Volume 10 | Number 4

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 29 Oct 2022]

[No new digest content identified]

Global Public Health

Volume 17, Issue 10 (2022)

<http://www.tandfonline.com/toc/rgph20/current>

(Re)imagining Research, Activism, and Rights at the Intersections of Sexuality, Health, and Social Justice

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 29 Oct 2022]

[No new digest content identified]

Health and Human Rights

Volume 24, Issue 1, June 2022

<https://www.hhrjournal.org/volume-24-issue-1-june-2022/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 17 - Issue 4 - October 2022

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 37, Issue 8, October 2022

<https://academic.oup.com/heapol/issue/37/8>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 29 Oct 2022]

[**What the policy and stewardship landscape of a national health research system looks like in a developing country like Iran: a qualitative study**](#)

Authors: Atousa Poursheikhali, Mohammed Alkhaldi, Reza Dehnavieh, AliAkbar Haghdooost, Ali Masoud, Somayeh Noorihemat, Mohammad Reza Cheshmyazdan and Mousa Bamir

Content type: Research 28 October 2022

Human Gene Therapy

Volume 33, Issue 17-18 / September 2022

<https://www.liebertpub.com/toc/hum/33/17-18>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 18, Issue 5, 2022

<https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList>

[Reviewed earlier]

Immunity

Oct 11, 2022 Volume 55 Issue 10 p1751-1966

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 29 Oct 2022]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 29 Oct 2022]

[**A decade of innovation to deepen the understanding of infectious diseases of poverty and foster their control and elimination**](#)

Authors: Dirk Engels, Sheng-lan Tang, Colin D. Butler, Ayoade M. J. Oduola, Tania C. de Araujo-Jorge, George F. Gao, Jürg Utzinger and Xiao-Nong Zhou

Content type: Editorial 24 October 2022

International Health

Volume 14, Issue 5, September 2022

<https://academic.oup.com/inthealth/issue/14/5>

[Reviewed earlier]

International Human Rights Law Review

Volume 11 (2022): Issue 1 (Jun 2022)

<https://brill.com/view/journals/hrlr/11/1/hrlr.11.issue-1.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 9, No 10 (2022) October 2022

<https://www.ijcmph.com/index.php/ijcmph/issue/view/92>

[Reviewed earlier]

International Journal of Epidemiology

Volume 51, Issue 5, October 2022

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 15 Issue 3, 2022

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3>

Special Issue: Children, young people and their international human right to healthcare

[Reviewed earlier]

JAMA

October 25, 2022, Vol 328, No. 16, Pages 1575-1652

<https://jamanetwork.com/journals/jama/currentissue>

Original Investigation

[Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19A Randomized Clinical Trial](#)

Susanna Naggie, MD, MHS; David R. Boulware, MD, MPH; Christopher J. Lindsell, PhD; et al.

free access has active quiz

JAMA. 2022;328(16):1595-1603. doi:10.1001/jama.2022.18590

This randomized clinical trial compares the efficacy of ivermectin vs placebo in shortening symptom duration among adult outpatients in the US with symptomatic mild to moderate COVID-19.

Key Points

Question Does ivermectin, 400 µg/kg, daily for 3 days, compared with placebo, shorten symptom duration among adult (≥30 years) outpatients in the US with symptomatic mild to moderate COVID-19?

Findings In this double-blinded, randomized, placebo-controlled platform trial conducted in the US during a period of Delta and Omicron variant predominance, and that included 1591 adult outpatients with COVID-19, the posterior probability of improvement in time to recovery in those treated with ivermectin vs placebo had a hazard ratio of 1.07, with a posterior probability of benefit of .91. This did not meet the prespecified threshold of posterior probability greater than .95.

Meaning These findings do not support the use of ivermectin in outpatients with mild to moderate COVID-19.

Viewpoint

[Preparing for Pandemics and Other Health Threats - Societal Approaches to Protect and Improve Health](#)

Thomas R. Frieden, MD, MPH; Amanda McClelland, RN, MPH

free access

JAMA. 2022;328(16):1585-1586. doi:10.1001/jama.2022.18877

This Viewpoint discusses 3 areas in need of progress regarding societal approaches to pandemics and other health threats: a renaissance in public health; robustness of primary health care; and resilience of individuals and communities, with higher levels of trust in government and society.

JAMA Pediatrics

October 2022, Vol 176, No. 10, Pages 959-1055
<https://jamanetwork.com/journals/jamapediatrics/currentissue>
[Reviewed earlier]

JBIR Evidence Synthesis

October 2022 - Volume 20 - Issue 10
<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>
[Reviewed earlier]

Journal of Adolescent Health

October 2022 Volume 71 Issue 4 p381-520
<https://www.jahonline.org/current>
[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 75 (2022)
<https://www.jair.org/index.php/jair>
Contents
[Reviewed earlier]

Journal of Community Health

Volume 47, issue 5, October 2022
<https://link.springer.com/journal/10900/volumes-and-issues/47-5>
[Reviewed earlier]

Journal of Development Economics

Volume 158 September 2022
<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/158/suppl/C>
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 17 Issue 4, October 2022
<http://journals.sagepub.com/toc/jre/current>
[Reviewed earlier]

Journal of Epidemiology & Community Health

September 2022 - Volume 76 - 9
<https://jech.bmj.com/content/76/9>
[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 15, Issue 3 Pages: 181-314 September 2022

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 18, Issue 1, 2022

<http://www.tandfonline.com/toc/rjge20/current>

Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications

Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 33, Number 3, August 2022

<https://muse.jhu.edu/issue/48370>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 24, issue 5, October 2022

<https://link.springer.com/journal/10903/volumes-and-issues/24-5>

Contents

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 20, 2022 _ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 226, Issue 7, 1 October 2022

<https://academic.oup.com/jid/issue/226/7>

[Reviewed earlier]

Journal of International Development

Volume 34, Issue 7 Pages: 1257-1452 October 2022

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

October 2022 - Volume 48 - 10

<http://jme.bmj.com/content/current>
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 9, Issue 3 (2022)

<https://institutionalrepository.aah.org/jpcrr/>
[Reviewed earlier]

Journal of Pediatrics

September 2022 Volume 248 p1-136

<http://www.jpeds.com/current>
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>
[Accessed 29 Oct 2022]

[Impact of university students' awareness and attitudes on vaccination practices for human papillomavirus, and perception on self-sampling for cervical cancer screening](#)

The burden of Human Papilloma Virus (HPV)-associated cancer remains high in developing nations.

Authors: Mathumalar Loganathan Fahrni, Muhamad Zabidi Azni, Nurhani Syafiqah Mohd Rusdi, Chee-Yan Choo, Khairil Anuar Md Isa and Zaheer-Ud-Din Babar

Citation: Journal of Pharmaceutical Policy and Practice 2022 15:73

Content type: Research Published on: 29 October 2022

[The procurement and supply chain strengthening project: improving public health supply chains for better access to HIV medicines, Uganda 2011–2016](#)

With countries moving towards reaching the UNAIDS 90-90-90 goal to achieve HIV epidemic control, there are going to be an unprecedented number of persons who will need to be tested, treated, and regularly monitored...

Authors: Sowedi Muyingo, David Etoori, Paul Lotay, Samuel Malamba, James Olweny, King Keesler, Steven Wiersma, Pito Jjemba and Rashid Settaala

Citation: Journal of Pharmaceutical Policy and Practice 2022 15:72

Content type: Research Published on: 27 October 2022

Journal of Public Health Management & Practice

September/October 2022 - Volume 28 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>
[Reviewed earlier]

Journal of Public Health Policy

Volume 43, issue 3, September 2022

<https://link.springer.com/journal/41271/volumes-and-issues/43-3>

Culture and COVID-19-related mortality: a cross-sectional study of 50 countries

Authors: Arnold Käffer, Jörg Mahlich

Content type: Original Article

Published: 22 August 2022

Pages: 413 - 430

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

October 2022 Volume 19 Issue 195

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 29, Issue 6, August 2022

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 96 Number 18 September 2022

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Oct 29, 2022 Volume 400 Number 10362 p1487-1556, e11

<https://www.thelancet.com/journals/lancet/issue/current>

Articles

9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea

Jeongha Mok, et al. on behalf of the MDR-END investigators

Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance

Dimitra Klapsa, et al.

Open Access

Review

Challenges and opportunities for educating health professionals after the COVID-19 pandemic

Julio Frenk, et al.

The Lancet Child & Adolescent Health

Oct 2022 Volume 6 Number 10 p667-746

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Oct 2022 Volume 4 Number 10 e698-e764

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Oct 2022 Volume 10 Number 10 e1360-e1533

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Oct 2022 Volume 22 Number 10 p1399-1512, e279-e309

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Oct 2022 Volume 7 Number 10 e801-e884

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Oct 2022 Volume 10 Number 10 p925-1008, e87-e93

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 26, issue 10, October 2022

<https://link.springer.com/journal/10995/volumes-and-issues/26-10>

[New issue; No digest content identified]

Medical Decision Making (MDM)

Volume 42 Issue 7, October 2022

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 100, Issue 3 Pages: 617-961 September 2022

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 610 Issue 7933, 27 October 2022

<https://www.nature.com/nature/volumes/610/issues/7933>

Editorial 26 Oct 2022

[Do the science on sustainability now](#)

The United Nations Sustainable Development Goals are not a priority for research in high-income countries. That must change.

Nature Biotechnology

Volume 40 Issue 10, October 2022

<https://www.nature.com/nbt/volumes/40/issues/10>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 29 Oct 2022)

[No new digest content identified]

Nature Genetics

Volume 54 Issue 10, October 2022

<https://www.nature.com/ng/volumes/54/issues/10>

[Reviewed earlier]

Nature Human Behaviour

Volume 6 Issue 10, October 2022

<https://www.nature.com/nathumbehav/volumes/6/issues/10>

[Reviewed earlier]

Nature Medicine

Volume 28 Issue 10, October 2022

<https://www.nature.com/nm/volumes/28/issues/10>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 21 Issue 10, October 2022

<https://www.nature.com/nrd/volumes/21/issues/10>

[Reviewed earlier]

Nature Reviews Genetics

Volume 23 Issue 10, October 2022

<https://www.nature.com/nrg/volumes/23/issues/10>

[Reviewed earlier]

Nature Reviews Immunology

Volume 22 Issue 10, October 2022

<https://www.nature.com/nri/volumes/22/issues/10>

[Reviewed earlier]

New England Journal of Medicine

October 20, 2022 Vol. 387 No. 17

<https://www.nejm.org/toc/nejm/medical-journal>

Perspective

[What Covid Has Taught the World about Ethics](#)

E.J. Emanuel, R.E.G. Upshur, and M.J. Smith

[Excerpt]

...The world has not yet had time to fully elucidate the lessons of Covid and apply them to preparations for future emergencies. But policymakers should heed the lessons of the pandemic by appreciating the ethical, not just the technical, dimensions of all challenges faced during emergencies; by starting from existing knowledge about the right values and principles to guide policy; and by ensuring that ethics expertise is present before an emergency response is conceived and is effectively integrated into decision making. Achieving these aims will require a sustained, focused effort to enhance ethics capacity at key global, national, and local public health organizations, academic institutions, and governmental agencies.

Editorials

[Audio Interview: Assessing the Effect of Vaccination and Prior SARS-CoV-2 Infection](#)

E.J. Rubin, L.R. Baden, and S. Morrissey

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 29 Oct 2022]

[No new digest content identified]

Pediatrics

Volume 150, Issue 4 October 2022

<https://publications.aap.org/pediatrics/issue/150/3>

[Reviewed earlier]

PharmacoEconomics

Volume 40, issue 10, October 2022

<https://link.springer.com/journal/40273/volumes-and-issues/40-10>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 29 Oct 2022)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 29 Oct 2022)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 29 Oct 2022)

[Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study](#)

Kathryn S. Hensley, Marlou J. Jongkees, Daryl Geers, Corine H. GeurtsvanKessel, Yvonne M. Mueller, Virgil A. S. H. Dalm, Grigorios Papageorgiou, Hanka Steggink, Alicja Gorska, Susanne Bogers, Jan G. den Hollander, Wouter F. W. Bierman, Luc B. S. Gelinck, Emile F. Schippers, Heidi S. M. Ammerlaan, Marc van der Valk, Marit G. A. van Vonderen, Corine E. Delsing, Elisabeth H. Gisolf, Anke H. W. Bruns, Fanny N. Lauw, Marvin A. H. Berrevoets, Kim C. E. Sigaloff, Robert Soetekouw, Judith Branger, Quirijn de Mast, Adriana J. J. Lammers, Selwyn H. Lowe, Rory D. de Vries, Peter D. Katsikis, Bart J. A. Rijnders, Kees Brinkman, Anna H. E. Roukens, Casper Rokx

Research Article | published 27 Oct 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003979>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 29 Oct 2022]

[Community structured model for vaccine strategies to control COVID19 spread: A mathematical study](#)

Elena Aruffo, Pei Yuan, Yi Tan, Evgenia Gatov, Effie Gournis, Sarah Collier, Nick Ogden, Jacques Bélair, Huaiping Zhu
Research Article | published 27 Oct 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0258648>

[Pregnant women's knowledge, attitude, and practice towards COVID-19 infection prevention in Ethiopia: A systematic review and meta-analysis](#)

Ayenew Mose, Amare Zewdie, Tadesse Sahle
Research Article | published 26 Oct 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0276692>

[On the relationship between conspiracy theory beliefs, misinformation, and vaccine hesitancy](#)

Adam M. Enders, Joseph Uscinski, Casey Klofstad, Justin Stoler
Research Article | published 26 Oct 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0276082>

[Data platforms for open life sciences—A systematic analysis of management instruments](#)

Daniel Laufs, Mareike Peters, Carsten Schultz
Research Article | published 25 Oct 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0276204>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 29 Oct 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

October 25, 2022 vol. 119 no. 43
<https://www.pnas.org/toc/pnas/119/43>
[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 37 - Issue 5 - October 2022
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>
[Reviewed earlier]

Preventive Medicine

Volume 163 October 2022
<https://www.sciencedirect.com/journal/preventive-medicine/vol/163/suppl/C>
[Reviewed earlier]

Proceedings of the Royal Society B

26 October 2022 Volume 289 Issue 1985
<https://royalsocietypublishing.org/toc/rspb/current>
[New issue; No digest content identified]

Public Health

Volume 211 Pages 1-170 (October 2022)
<https://www.sciencedirect.com/journal/public-health/vol/211/suppl/C>
[Reviewed earlier]

Public Health Ethics

Volume 15, Issue 1, April 2022
<http://phe.oxfordjournals.org/content/current>
[Reviewed earlier]

Public Health Reports

Volume 137 Issue 5, September/October 2022
<https://journals.sagepub.com/toc/phrg/137/5>
[Reviewed earlier]

Qualitative Health Research

Volume 32 Issue 12, October 2022
<https://journals.sagepub.com/toc/qhra/current>
[Reviewed earlier]

Research Ethics

Volume 18 Issue 4, October 2022
<http://journals.sagepub.com/toc/reab/current>
[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>
[Accessed 29 Oct 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

25 Oct 2022

[Telemedicine: validation of a questionnaire to evaluate the experience of health professionals](#)

Original research | Spanish |

25 Oct 2022

National and regional social observatories of tuberculosis in eight countries in Latin America and the Caribbean

Special report | Spanish |

Risk Analysis

Volume 42, Issue 9 Pages: 1893-2124 September 2022

<https://onlinelibrary.wiley.com/toc/15396924/current>

Special Series: Systemic Risks

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 29 Oct 2022]

[No new digest content identified]

Science

Volume 378| Issue 6618| 28 Oct 2022

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 28, issue 5, October 2022

<https://link.springer.com/journal/11948/volumes-and-issues/28-5>

[Reviewed earlier]

Science Translational Medicine

Volume 14| Issue 668| 26 Oct 2022

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Social Science & Medicine

Volume 308 September 2022

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/308/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 29 Oct 2022]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 43, issue 2-3, June 2022

<https://link.springer.com/journal/1117/volumes-and-issues/43-2>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 49 September–October 2022

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/49/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 27, Issue 10 Pages: i-iv, 841-940 October 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 40, Issue 43 Pages 6189-6304 (12 October 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/43>

Discussion Full text access

[How health workers can make a difference in the public COVID-19 vaccination response](#)

Katrine B. Habersaat, Sideeka Narayan, Siff Malue Nielsen, Martha Scherzer, ... Holly Seale

Pages 6192-6195

Short communication Full text access

[Covid-19 vaccine hesitancy and resistance amongst parents of children under 18 years of age in Ireland](#)

Ruth Ceannt, Frederique Vallieres, Heather Burns, Jamie Murphy, Philip Hyland

Pages 6196-6200

Research article Full text access

[The connection between COVID-19 vaccine abundance, vaccination coverage, and public trust in government across the globe](#)

Ida G. Monfared

Pages 6211-6217

Research article Abstract only

[Impacts of Catch-Up Immunization program with the 13-Valent pneumococcal Conjugate vaccine in Taiwan: Focus on age-stratified differences and high-risk population \(2001–2015\)](#)

Shih-Tsung Huang, Yhu-Chering Huang, Edward Kuo, Ya-Min Yang, Fei-Yuan Hsiao

Pages 6225-6234

Research article Open access

Can financial incentives and other nudges increase COVID-19 vaccinations among the vaccine hesitant? A randomized trial

Mireille Jacobson, Tom Y. Chang, Manisha Shah, Rajiv Pramanik, Samir B. Shah
Pages 6235-6242

Japanese Society of Vaccinology

Research article Abstract only

Proposal for the revision of guidelines for clinical trials of vaccines to prevent infectious diseases in Japan

Yumiko Nomura, Kiyohito Noda, Yuusuke Oohashi, Shin Okuda, ... Nobuhiko Okabe
Pages 6295-6304

Value in Health

October 2022 Volume 25 Issue 10 p1663-1804

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....

.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

Selected Research

No new digest content identified.

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

[Filter: All articles]

Selected Research

Estimating the impact of implementation and timing of COVID-19 vaccination programme in Brazil: a counterfactual analysis

Leonardo Souto Ferreira, Flávia Maria Darcie Marquitti, Rafael Lopes Paixão da Silva, Marcelo Eduardo Borges, Marcelo Ferreira da Costa Gomes, Oswaldo Gonçalves Cruz, Roberto André Kraenkel, Renato Mendes Coutinho, Paulo Inácio Prado, Leonardo Soares Bastos

medRxiv 2021.12.24.21268384; doi: <https://doi.org/10.1101/2021.12.24.21268384> Revision

On the frontlines in Shanghai: Stress, burnout and perceived benefit among COVID-19 testers and other personnel during the Omicron wave lockdown

Zhimin Xu, Xia Liu, Gabriela L M Ghisi, Lixian Cui, Sherry L Grace

medRxiv 2022.10.25.22281504; doi: <https://doi.org/10.1101/2022.10.25.22281504>

Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India

Seth A Hoffman, Christopher LeBoa, Kashmira Date, Pradeep Haldar, Pauline Harvey, Rahul Shimpi, Qian An, Chenhua Zhang, Niniya Jayaprasad, Lily Horng, Kirsten Fagerli, Priyanka Borhade, Debjit Chakraborty, Sunil Bahl, Arun Katkar, Abhishek Kunwar, Vijay Yewale, Jason R Andrews, Pankaj Bhatnagar, Shanta Dutta, Stephen P Luby

medRxiv 2022.10.26.22281529; doi: <https://doi.org/10.1101/2022.10.26.22281529>

What is the current state of public health system preparedness for infectious disease emergencies? A scoping review

Jessica M Lee, Rachel Jansen, Kate E Sanderson, Fiona Guerra, Sue Keller-Olaman, Michelle Murti, Tracey L O'Sullivan, Madelyn P Law, Brian Schwartz, Laura E Bourns, Yasmin Khan

medRxiv 2022.10.25.22281308; doi: <https://doi.org/10.1101/2022.10.25.22281308>

Bell's Palsy Following SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis

Ali Rafati, Yeganeh Pasebani, Melika Jameie, Yuchen Yang, Mana Jameie, Saba Ilkhani, Mobina Amanollahi, Delaram Sakhaei, Mehran Rahimlou, Amir Kheradmand

medRxiv 2022.10.26.22281537; doi: <https://doi.org/10.1101/2022.10.26.22281537>

The pervasive association between political ideology and COVID-19 vaccine uptake in Brazil: an ecologic study

Gabriel J. Seara-Morais, Thiago J. Avelino-Silva, Marcia Couto, Vivian I. Avelino-Silva

medRxiv 2022.10.24.22281482; doi: <https://doi.org/10.1101/2022.10.24.22281482>

Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults

Jennifer L Farrar, Lana Childs, Mahamoudou Ouattara, Fahmina Akhter, Amadea Britton, Tamara Pilishvili, Miwako Kobayashi

medRxiv 2022.10.06.22280772; doi: <https://doi.org/10.1101/2022.10.06.22280772> Revision

COVID-19 vaccine equity and the right to health for displaced Venezuelans in Latin America

David C. Hill, Zafiro Andrade-Romo, Karla Solari, Ellithia Adams, Lisa Forman, Daniel Grace, Alfonso Silva-Santisteban, Amaya Perez-Brumer

medRxiv 2022.10.21.22281363; doi: <https://doi.org/10.1101/2022.10.21.22281363>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Accessed 29 Oct 2022]

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

Acquire wealth, avoid debt: exploring households' livelihood and financial resilience amid the COVID-19 in a developing country

Quy Van Khuc

Thuy Nguyen

Hong-Hai Ho

Last edited: Oct 29, 2022 UTC

Business Social and Behavioral Sciences Economics Counseling Psychology Business Administration, Management, and Operations International and Area Studies Applied Behavior Analysis financial literacy, financial investment, household financial, livelihood, Vietnam

OSF Preprints

Systematic overview of challenges and opportunities of computational data-driven research in biology

Tejasvene Ramesh

Karishma Chhugani

Vanessa Jönsson

MANGUL, SERGHEI

Last edited: Oct 25, 2022 UTC

Life Sciences Biotechnology Medicine and Health Sciences Genetics and Genomics Bioinformatics Biology

During the past decade, the rapid advancement of high-throughput technologies has reshaped modern biomedical research by vastly extending the diversity, richness, and availability of data and methods across various domains. Currently, computational researchers are empowered with data, methods, and t ...

OSF Preprints

Evidence from 35 countries that the social perception of key protagonists is associated with containment measures during the COVID-19 pandemic

Maria-Therese Friebs

Patrick Kotzur

Christine Kraus

Moritz Schemmerling

Jessica Alina Herzig

Adrian Stanciu

Sebastian Dilly

Lisa Hellert

Doreen Hübner

Anja Rückwardt

+56

Last edited: Oct 24, 2022 UTC

Social and Behavioral Sciences Psychology Social Psychology

It is crucial to understand why people comply with measures to contain viruses and their effects during pandemics. We provide evidence from 35 countries ($N_{\text{total}} = 12,553$) from six continents during the COVID-19 pandemic that the social perception of key protagonists on two basic dimensions of social ...

OSF Preprints

Wellcome Open Research [to 29 Oct 2022]
<https://wellcomeopenresearch.org/browse/articles>
[Accessed 29 Oct 2022]
Selected Research
No new digest content identified

* * * *

Think Tanks

Brookings [to 29 Oct 2022]
<http://www.brookings.edu/>
Latest Research [Selected]
No new digest content identified

Center for Global Development [to 29 Oct 2022]
<https://www.cgdev.org/>
All Research [Selected]
No new digest content identified

Chatham House [to 29 Oct 2022]
<https://www.chathamhouse.org/>
Selected Analysis, Comment
No new digest content identified

CSIS [to 29 Oct 2022]
<https://www.csis.org/>
Selected Reports Report
No new digest content identified.

Kaiser Family Foundation [to 29 Oct 2022]
https://www.kff.org/search/?post_type=press-release
Press Releases

[State Medicaid Officials Anticipate the COVID-19 Public Health Emergency Will End During State FY 2023, Leading to Medicaid Enrollment Declines, Slower Total Medicaid Spending Growth and a Sharp Rise in States' Share of Costs](#)

After steep gains since 2020, state Medicaid agencies expect Medicaid enrollment to begin to decline in FY 2023, following the expiration of the COVID-19 public health emergency (PHE), which most states assumed would occur during FY 2023, according to KFF's new state Medicaid budget survey. Projections of declining enrollment tied...

ODI [Overseas Development Institute] [to 29 Oct 2022]

<https://odi.org/en/publications/>
Publications
No new digest content identified.

Pew Research Center [to29 Oct 2022]

<https://www.pewresearch.org/>

Latest Publications Report | Oct 25, 2022

Americans Value U.S. Role as Scientific Leader, but 38% Say Country Is Losing Ground Globally

Large majorities value government investments in science and consider it important for the United States to be a world leader in scientific achievement, but few think the country is gaining ground globally.

Rand [to29 Oct 2022]

<https://www.rand.org/pubs.html>

Reports, Selected Journal Articles

No new digest content identified.

Urban Institute [to29 Oct 2022]

<https://www.urban.org/publications>

New Research Publications

World Economic Forum [to29 Oct 2022]

<https://www.weforum.org/press/>

Media

No new digest content identified.

*	*	*	*
*	*	*	*

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#))/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#) , [PATH](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*